HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Takagi, Y. Articles by Hirabuki, N. Search for Related Content PubMed PubMed Citation Articles by Takagi, Y. Articles by Hirabuki, N. Agricola Articles by Takagi, Y. Articles by Hirabuki, N.

Evaluation of indexes of in vivo manganese status and the optimal intravenous dose for adult patients undergoing home parenteral nutrition^1,2,3

¹ From the Department of Maternity and Child Nursing, the School of Allied Health Sciences, Faculty of Medicine, Osaka University, Japan; and the Departments of Pediatric Surgery and Radiology, Osaka University Medical School, Japan.

² Supported by a Grant-in-aid for Scientific Research (09470249) from the Ministry of Education.

³ Address reprint requests to Y Takagi, Department of Maternity and Child Nursing, School of Allied Health Sciences, Faculty of Medicine, Osaka University 1-7, Yamadaoka, Suita, Osaka, Japan, 565-0871. E-mail: takagi{at}sahs.med.osaka-u.ac.jp.

	ABSTRACT

TOP ABSTRACT INTRODUCTION SUBJECTS AND METHODS RESULTS DISCUSSION REFERENCES

 
Background: There are no accurate indexes for determining the status of manganese in humans, and there is no clear recommended daily dose of this essential trace element to be administered in total parenteral nutrition solutions.

Objective: The objectives were to evaluate accurate indexes of manganese status and elucidate the optimal manganese dose to be administered to adult patients undergoing home parenteral nutrition.

Design: Patients were administered total parenteral nutrition solutions providing 0, 1, 2, or 20 µmol Mn/d according to an on-off design, after which manganese concentrations in whole blood and plasma were determined. Magnetic resonance imaging (MRI) was performed to determine the intensity on T₁-weighted images (MRI intensity) and T₁ values in the globus pallidus. Hematologic and biochemistry tests were also performed.

Results: High degrees of correlation were found between whole-blood manganese concentrations and both MRI intensity (r = 0.7728) and T₁ values (r = -0.7519) in the globus pallidus. A strong negative correlation was found between MRI intensity and T₁ values (r = -0.8407). The dose of 1 µmol Mn/d caused no change in MRI intensity or T₁ values, and the whole-blood manganese concentration remained within the normal range in all patients.

Conclusions: Whole-blood manganese concentrations and MRI intensity and T₁ values in the globus pallidus are useful indexes of the status of manganese in humans. The optimal dose of manganese may be 1 µmol/d for adult patients undergoing home parenteral nutrition.

Key Words: Home parenteral nutrition • total parenteral nutrition • magnetic resonance imaging • manganese • trace elements • nutritional requirements • optimal dose

	INTRODUCTION

TOP ABSTRACT INTRODUCTION SUBJECTS AND METHODS RESULTS DISCUSSION REFERENCES

 
Manganese is considered an essential trace element for humans (1) and is ordinarily administered in total parenteral nutrition (TPN) solutions, but the kinetics of manganese in the body have yet to be elucidated. Moreover, there are no generally accepted indexes for use in determining the status (excess or deficiency) of manganese in the body. There is also no clear, standard recommended daily dose of this element. The published literature indicates a broad, 200-fold range in the recommended daily manganese dose for adults, extending from a low dose of 0.18–0.91 µmol (0.01-0.05 mg) (2) to a high dose of 40 µmol (2.2 mg) (3).

The past decade has brought reports that magnetic resonance imaging (MRI) can detect accumulation of manganese in the brain and that T₁-weighted magnetic resonance images have shown high intensity in the basal ganglia, especially in the globus pallidus, of patients receiving TPN. These findings are thought to be due to excess administration of manganese (4–7). However, there have been no reports of clinical studies on relations or correlations among blood manganese concentrations, intensity on T₁-weighted images (MRI intensity), and T₁ values.

Accordingly, the present study was designed to elucidate MRI intensity and T₁ values in the globus pallidus of patients undergoing home parenteral nutrition (HPN) and to investigate the relations between blood manganese concentrations and these 2 MRI variables at the time of TPN administration. We also evaluated the optimal intravenous dose of manganese on the basis of these variables. This is the first report of a dose-response study of manganese in HPN patients.

	SUBJECTS AND METHODS

TOP ABSTRACT INTRODUCTION SUBJECTS AND METHODS RESULTS DISCUSSION REFERENCES

 
Subjects
This study was conducted between May 1994 and March 1999 in 12 patients (6 men and 6 women) undergoing long-term HPN under the care of the Department of Pediatric Surgery, Osaka University Medical School, Japan. None of the subjects had serious liver dysfunction at the time of enrollment. Patient characteristics at the time of enrollment, including information on manganese administration, are shown in Table 1. The patients ranged in age from 17 to 62 y. Four patients had short-bowel syndrome, 3 had Crohn disease, 2 had chronic idiopathic intestinal pseudoobstruction syndrome, 1 had sitophobia, 1 had enteritis, and 1 had intestinal ulcers.

Rationale for selection of manganese doses
In Japan, the only commercially available trace element preparation provides the following elements daily: 20 µmol Mn, 35 µmol Fe, 5 µmol Cu, 60 µmol Zn, and 1 µmol I. For our study, the Osaka University Hospital changed the concentration of manganese while keeping the compounded amounts of the other 4 elements constant by varying the proportion of a solution containing no manganese (FeCl₂, CuCl₂, ZnSO₄, and KI) and a solution containing only manganese (MnCl₂).

In our study, 9 patients were administered manganese in a dose sequence of 20 0 2 1 µmol/d and 3 patients received manganese in a dose sequence of 20 2 1 µmol/d (Table 1). Before the study began, all 12 patients had received TPN supplemented with a trace element preparation that included 20 µmol Mn/d, and 9 of the 12 patients had undergone an on-off study in which the whole-blood and plasma manganese concentrations and MRI intensity of the globus pallidus were determined at 20 or 0 µmol Mn/d (8). The reproducibilities and reversibilities of these 3 variables and of T₁ values were investigated. On the basis of Shike et al's (9) recommendation that 0.18-1.82 µmol Mn/d (0.01-0.1 mg Mn/d) be added to TPN solutions, we selected 2 µmol Mn/d as the next dose to investigate. Because the MRI intensity in the globus pallidus increased slightly after this dose, we reduced the next dose to be investigated to 1 µmol Mn/d.

Measurement of variables
The clinical variables of each patient were monitored, and whole-blood and plasma manganese concentrations were measured at 1-mo intervals. In addition, serum variables were measured (iron, copper, zinc, unbound iron binding capacity, and ferritin) and hematologic (eg, white blood cells, red blood cells, platelets, hemoglobin, hematocrit) and blood biochemistry (eg, glucose, electrolytes, blood urea nitrogen, creatinine, aspartate aminotransferase, alanine aminotransferase, -glutamyltransferase, bilirubin, C-reactive protein, total protein, albumin, lactate dehydrogenase, leucine aminopeptidase, alkaline phosphatase, cholinesterase, creatine kinase, total cholesterol, ester cholesterol, amylase, lipase, triacylglycerol, phospholipids, fatty acids) variables were measured about every 2-3 mo.

Blood was collected from all subjects with use of a disposable polypropylene syringe and a needle (Terumo, Tokyo). Whole-blood and plasma manganese concentrations were measured according to the procedures described by Matsuda et al (10, 11) with use of an atomic absorption spectrophotometer equipped with a graphite furnace (model 5700 or Z-8100; Hitachi, Tokyo) after dilution with 0.5% Triton X-100 (Wako Pure Chemical Industries, Osaka, Japan). To avoid contamination by manganese, all tools used for sampling and analysis (except for syringes and needles) were submerged in 6 mol HNO₃/L for (7 d before use. To ensure quality control, bovine liver 1577b and bovine serum standard reference material (SRM-1598; National Institute of Standards and Technology, Gaithersburg, MD) were analyzed along with the whole-blood and plasma samples.

MRI of the brain was performed about every 2-3 mo with a Magnetom H15 instrument (Siemens, Erlangen, Germany) with use of repetition times (TR) of 660 and 2500 ms and an echo time (TE) of 15 ms. Radiologists rated the intensity of the images as high when the globus pallidus showed a high-intensity signal on the T₁-weighted image, as moderate when the increase in intensity was slight, and none when there was no increase in intensity. The T₁ value was calculated as follows:

(1)

(2)

(3)

((4))

where S is signal intensity and M_o is proton density.

Statistical analysis
On the basis of our time-course data for the change in the whole-blood manganese concentrations in response to changes in the administered dose of manganese, we judged that the concentration became stable after 6 mo of administration of a new dose. In addition, when the manganese dose was changed in our previous on-off study, whole-blood and plasma manganese concentrations and the MRI intensity and T₁ values in the globus pallidus were reproducible and reversible (8). Thus, we decided to calculate the mean for each of these variables 6 mo after the start of a new manganese dose, and these values are presented as means (±SDs) or as the percentage distribution of the representative data. Because the variables of interest were reproducible, we included blood and MRI data from patient 6 (who received 20 µmol Mn/d for 4.6 mo in the current study but previously received this dose for >6 mo) and MRI data from patient 11 (who did not receive 0 µmol Mn/d in the current study but previously received manganese-free TPN solutions for >6 mo) in the analysis.

For multiple comparisons between diets (HPN with 20 µmol Mn/d, ED, normal diet), we used the Tukey-Kramer test with the error from one-way analysis of variance for whole-blood and plasma manganese concentrations, Wilcoxon's test for MRI intensity, and unpaired Student's t test for T₁ values. For multiple comparisons between administered manganese doses (0, 1, 2, and 20 µmol/d), we used the Tukey-Kramer test with the error of variance calculated considering the correlations and the missing MRI data resulting from equipment malfunction, patients being admitted to other hospitals, and canceled appointments (SAS-GLM version 6.12; SAS Institute, Cary, NC).

Whole-blood and plasma manganese concentrations and T₁ values in the globus pallidus were transformed logarithmically for statistical testing. MRI intensity was scored as 2 when the rating was high, 1 when moderate, and 0 when none. The level of statistical significance was set at P = 0.05.

	RESULTS

TOP ABSTRACT INTRODUCTION SUBJECTS AND METHODS RESULTS DISCUSSION REFERENCES

 
Clinical findings
During the course of this study, none of the patients showed any clinical symptoms of manganese intoxication (eg, Parkinsonian-like neurologic abnormalities) or deficiency (eg, abnormalities in lipid metabolism) that could be attributed to manganese administration. In addition, none of the patients developed serious liver dysfunction [aspartate aminotransferase >100 U/L, alanine aminotransferase >100 U/L, and total bilirubin >3.4 µmol/L (2 mg/dL)]. None of the serum, hematologic, or biochemical variables was dependent on the administered manganese dose. Whole-blood and plasma manganese concentrations, MRI intensity and T₁ values, and manganese doses for a representative patient in the study (ie, patient 2) are shown in Figure 1.

View larger version (25K): [in this window] [in a new window]   FIGURE 1. Whole-blood and plasma manganese concentrations, intensity of magnetic resonance imaging (MRI) and T1–weighted magnetic resonance images in the globus pallidus, and manganese doses in a typical male patient (aged 34 y) who underwent home parenteral nutrition in July 1994. The gray-shaded area in the top 2 panels indicates our normal ranges.

View larger version (19K): [in this window] [in a new window]   FIGURE 2. Mean (±SD) whole-blood and plasma manganese concentrations, intensity of magnetic resonance imaging (MRI) in the globus pallidus, and T1-weighted magnetic resonance images in the globus pallidus of home parenteral nutrition patients (HPN) who received a trace element preparation (20 µmol Mn/d), of patients administered an elemental diet (ED) daily for 1 y before entry into the present study, and of healthy control subjects. Bars with different letters are significantly different, P < 0.05 (Tukey-Kramer multiple comparisons test). *Significantly different from ED, P < 0.05 (Wilcoxon's test). n in brackets.

View larger version (24K): [in this window] [in a new window]   FIGURE 3. Mean (±SD) whole-blood and plasma manganese concentrations, intensity of magnetic resonance imaging (MRI) in the globus pallidus, and T1-weighted magnetic resonance images in the globus pallidus of home parenteral nutrition patients who received a trace element preparation [0, 1, 2, or 20 µmol Mn/d via total parenteral nutrition (TPN)]. Bars with different letters are significantly different, P < 0.05 (Tukey-Kramer multiple comparisons test). n in brackets.

View larger version (30K): [in this window] [in a new window]   FIGURE 4. Distribution of whole-blood manganese concentrations in home parenteral nutrition patients who received a trace element preparation [0, 1, 2, or 20 µmol Mn/d via total parenteral nutrition (TPN)], of patients administered an elemental diet (ED) daily for 1 y before entry into the present study, and of healthy control subjects.

View larger version (10K): [in this window] [in a new window]   FIGURE 5. Magnetic resonance imaging (MRI) intensity on T1-weighted images and T1 values in the globus pallidus of home parenteral nutrition patients who received a trace element preparation providing 0 (), 1 (•), 2 (), or 20 () µmol Mn/d.

	DISCUSSION

TOP ABSTRACT INTRODUCTION SUBJECTS AND METHODS RESULTS DISCUSSION REFERENCES

The signal intensity in MRI is dependent on (4 variables intrinsic to tissues: the proton density, T₁ relaxation time, T₂ relaxation time, and flow. T₁-weighted images show contrast mainly due to differences in the T₁ value. It is known that the intensity on T₁-weighted images increases as the T₁ value becomes shorter.

Manganese is a paramagnetic substance, and it is generally accepted that paramagnetic substances may shorten the T₁ value. In an in vitro study using manganese and trace element (iron, copper, zinc, and iodine) solutions diluted with physiologic saline or rat brain homogenate, Chaki et al (12) observed concentration-dependent signal hyperintensity only for the solutions that contained manganese; no effect was observed for solution without manganese. The same team also reported that certain brain sites in rats that received TPN showed a strong positive correlation between whole-blood manganese concentrations and the signal intensity on T₁-weighted images (13). Thus, the general consensus is that during parenteral nutrition, T₁ shortening is due to manganese accumulation.

In the present study, the mean MRI intensity and T₁ value in the globus pallidus showed a strong and negative correlation (Table 2). These 2 variables changed in a manganese dose-dependent manner when the administered doses of the other 4 trace elements (iron, copper, zinc, and iodine) were kept constant. The T₁ value is influenced by both the conditions of measurement and the equipment used. Therefore, we surmise that, as long as a patient is evaluated under the same conditions of measurement and with the same equipment, the T₁ value in the globus pallidus is more objective than are MRI findings as an index of the in vivo manganese status.

Whole-blood manganese concentrations in our 40 healthy volunteers was similar to other reported values (11, 14–18). On the other hand, the range of plasma manganese concentrations in these volunteers (0.0346–0.105 µmol/L, or 1.9-5.8 µg/L) was 2-3 times that of other reported values (11, 14–20). The reason for this difference is not clear; there may have been something atypical about the plasma manganese concentrations in our control group. Even so, one of our most important findings was that the whole-blood manganese concentration correlated strongly with both MRI intensity and the T₁ value, whereas the plasma manganese concentration correlated weakly with both of these MRI variables (Table 2). In addition, Alves et al (19) reported that high intensity was observed even when the plasma manganese concentration was maintained in the normal range. We thus surmise that the manganese concentration in whole blood is superior to that in plasma as an index of MRI intensity and the T₁ value; other investigators showed that it is also superior as an index of the manganese status in the body (14–16, 19, 21).

On the basis of these findings, we conclude that the whole-blood manganese concentration, MRI intensity in the globus pallidus, and the T₁ value in the globus pallidus are useful indexes of in vivo manganese status. All 3 variables changed in a manganese dose-dependent manner. The T₁ value was significantly shorter when HPN patients were administered 2 or 20 µmol Mn/d than when administered 0 or 1 µmol/d, which suggests that the manganese concentration in the brain increased at the higher doses. Fitzgerald et al (21) postulated that the optimal dose of manganese for HPN patients is 2 µmol/d. However, Bertinet et al (16) reported that when the manganese dose for HPN patients was 2 µmol/d, the T₁-weighted images showed a high-intensity signal in the basal ganglia of 10 patients (71%) and that 1.82 µmol Mn/d (0.1 mg Mn/d) is probably still excessive.

The results depicted in Figure 5, the fact that the differences in T₁ values at 0 and 1 µmol Mn/d were not significant, and the finding that whole-blood manganese concentrations were within the normal range in all HPN patients at 0 or 1 µmol Mn/d (although the mean concentration was significantly higher at 1 than at 0 µmol Mn/d) confirm the efficacy of manganese administered at a dose of 1 µmol/d. This dose is within the range recommended by the American Medical Association (0.18-0.91 µmol/d, or 0.01-0.05 mg/d; 2) and by the American Society for Parenteral and Enteral Nutrition (1.01-1.82 µmol/d, or 60-100 µg/d; 22).

We determined the concentration of manganese received as a contaminant in the parenteral solutions used. The manganese concentration was 0.0364–0.0728 µmol/L (2-4 µg/L) in the glucose and electrolyte solutions and was <0.0091 µmol/L (0.5 µg/L) in the amino acid solutions. The manganese concentration received by our HPN patients as contaminants (1200 mL glucose and electrolyte solution + 600 mL amino acid solution each day) was thus 0.05-0.11 µmol/d (3-6 µg/d). Isegawa et al (23) reported that the level of contamination in the solutions commercially available in Japan was <0.0275 µmol Mn/L (1.5 µg Mn/L) for lipid solutions and <0.0018 µmol Mn/vial (0.1 µg Mn/vial) for vitamin, insulin, and heparin preparations. In addition, manganese elucidated from and adsorbed to bags, infusion devices, catheters, and filters commercially available in Japan totals <0.018 µmol/L, or <1 µg/L (J Isegawa, Ajinomoto Co, Inc, unpublished observations, 2001). Thus, manganese contamination was relatively small.

Because none of the patients showed any clinical (including neurologic) symptoms suggestive of manganese intoxication or deficiency, it may be that functional changes are less sensitive to in vivo manganese status than are MRI-detected changes.

On the basis of our findings, we conclude that the whole-blood manganese concentration, the MRI intensity in the globus pallidus, and the T₁ value in the globus pallidus are useful indexes for evaluating the manganese status in humans. We propose that the optimal dose of manganese in TPN solutions is 1 µmol/d for adult HPN patients.

	REFERENCES

TOP ABSTRACT INTRODUCTION SUBJECTS AND METHODS RESULTS DISCUSSION REFERENCES

 

1. Leach RM Jr. Metabolism and function of manganese. In: Prasad AS, ed. Trace elements in human health and disease. Vol 2. New York: Academic Press, 1976:235–47.
2. American Medical Association. Electrolytes, minerals, and trace elements: recommended daily intravenous intake during TPN. In: Drug evaluations annual. Milwaukee: American Medical Association, 1995:2311–2.
3. Wretlind A. Complete intravenous nutrition: theoretical and experimental background. Nutr Metab 1972;14(suppl):1–57.
4. Ono J, Harada K, Kodaka R, et al. Manganese deposition in the brain during long-term total parenteral nutrition. J Parenter Enteral Nutr 1995;19:310–2.[Abstract]
5. Mirowitz SA, Westrich TJ, Hirsch JD. Hyperintense basal ganglia on T₁-weighted MR images in patients receiving parenteral nutrition. Radiology 1991;181:117–20.[Abstract/Free Full Text]
6. Mirowitz SA, Westrich TJ. Basal ganglia signal intensity alterations: reversal after discontinuation of parenteral manganese administration. Radiology 1992;185:535–6.[Abstract/Free Full Text]
7. Ejima A, Imamura T, Nakamura S, Saito H, Matsumoto K, Momono S. Manganese intoxication during total parenteral nutrition. Lancet 1992;339:426.[Medline]
8. Takagi Y, Okada A, Sando K, Wasa M, Yoshida H, Hirabuki N. On-off study of manganese administration to adult patients undergoing home parenteral nutrition: new indices of in vivo manganese level. J Parenter Enteral Nutr 2001;25:87–92.[Abstract]
9. Shike M, Ritchie M, Shils ME, et al. Manganese status in long-term home TPN patients. Clin Res 1986;34:804A (abstr).
10. Matsuda A, Kimura M, Kataoka M, Ohkuma S, Sato M, Itokawa Y. Quantifying manganese in lymphocytes to assess manganese nutritional status. Clin Chem 1989;35:1939–41.[Abstract/Free Full Text]
11. Matsuda A, Kimura M, Takeda T, Kataoka M, Sato M, Itokawa Y. Changes in manganese content of mononuclear blood cells in patients receiving total parenteral nutrition. Clin Chem 1994;40:829–32.[Abstract/Free Full Text]
12. Chaki H, Matsuda A, Yamamoto K, et al. Significance of magnetic resonance image and blood manganese measurement for the assessment of brain manganese during total parenteral nutrition in rats. Biol Trace Elem Res 1998;63:37–50.[Medline]
13. Chaki H, Furuta S, Matsuda A, et al. Magnetic resonance image and blood manganese concentration as indices for manganese content in the brain of rats. Biol Trace Elem Res 2000;74:245–57.[Medline]
14. Mehta R, Reilly JJ. Manganese levels in a jaundiced long-term total parenteral nutrition patient: potentiation of haloperidol toxicity? Case report and literature review. J Parenter Enteral Nutr 1990;14:428–30.[Abstract]
15. Wardle CA, Forbes A, Roberts NB, Jawhari AV, Shenkin A. Hypermanganesemia in long-term intravenous nutrition and chronic liver disease. J Parenter Enteral Nutr 1999;23:350–5.[Abstract]
16. Bertinet DB, Tinivella M, Balzola FA, et al. Brain manganese deposition and blood levels in patients undergoing home parenteral nutrition. J Parenter Enteral Nutr 2000;24:223–7.[Abstract]
17. Friedman BJ, Freeland-Graves JH, Bales CW, et al. Manganese balance and clinical observations in young men fed a manganese-deficient diet. J Nutr 1987;117:133–43.
18. Freeland-Graves JH, Behmardi F, Bales CW, et al. Metabolic balance of manganese in young men consuming diets containing five levels of dietary manganese. J Nutr 1988;118:764–73.
19. Alves G, Theibot J, Tracqui A, Delangre T, Guedon C, Lerebours E. Neurologic disorders due to brain manganese deposition in a jaundiced patient receiving long-term parenteral nutrition. J Parenter Enteral Nutr 1997;21:41–5.[Abstract]
20. Malone M, Shenkin A, Fell GS, Irving MH. Evaluation of a trace element preparation in patients receiving home intravenous nutrition. Clin Nutr 1989;8:307–12.
21. Fitzgerald K, Mikalunas V, Rubin H, McCarthy R, Vanagunas A, Craig RM. Hypermanganesemia in patients receiving total parenteral nutrition. J Parenter Enteral Nutr 1999;23:333–6.[Abstract]
22. National Advisory Group on Standards and Practice Guidelines for Parenteral Nutrition. Safe practice for parenteral nutrition formulation. J Parenter Enteral Nutr 1998;22:49–66.[Medline]
23. Isegawa J, Terashima T, Sato M. Trace element (iron, zinc, copper, manganese and iodine) contents contaminated in the preparations commercially available in Japan. Jpn J Parenter Enteral Nutr 1990;12:522–5 (in Japanese).

This article has been cited by other articles:

				L. Howard, C. Ashley, D. Lyon, and A. Shenkin Autopsy Tissue Trace Elements in 8 Long-Term Parenteral Nutrition Patients Who Received the Current U.S. Food and Drug Administration Formulation JPEN J Parenter Enteral Nutr, September 1, 2007; 31(5): 388 - 396. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Takagi, Y. Articles by Hirabuki, N. Search for Related Content PubMed PubMed Citation Articles by Takagi, Y. Articles by Hirabuki, N. Agricola Articles by Takagi, Y. Articles by Hirabuki, N.